SCHEDULE: Laurence Lytton Discloses 1% Stake in Exagen Inc.
Beneficial Ownership Disclosure
Laurence W. Lytton reported a 1.0% beneficial ownership stake in Exagen Inc., holding 216,840 shares of common stock as of June 30, 2025.
Summary
- Laurence W. Lytton reported beneficial ownership of 216,840 shares of Exagen Inc. common stock.
- This represents 1.0% of the company's outstanding common stock.
- The percentage is calculated based on 22,003,641 shares of Common Stock outstanding as of July 24, 2025.
- The outstanding shares figure was reported in Exagen Inc.'s Form 10-Q filed on July 29, 2025.
- The filing is an Amendment No. 3 to a Schedule 13G.
- Laurence W. Lytton holds sole voting power and sole dispositive power over all 216,840 shares.
- The securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a passive ownership stake, providing no new operational or financial information about the company itself.
Positives
- No specific positive financial or operational developments are disclosed in this passive ownership filing.
Negatives
- No specific negative financial or operational developments are disclosed in this passive ownership filing.
Risks
- This filing, a passive ownership disclosure, does not detail specific company risks.
Future Outlook
This filing is a passive ownership disclosure and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine disclosure of a passive ownership stake by an individual and does not provide information related to broader industry trends or competitors.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency on a significant individual ownership stake, though it is below the 5% threshold for active investor status.
Key Dates
| Date | Description |
|---|---|
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-07-24 | Date as of which 22,003,641 shares of Common Stock were outstanding. |
| 2025-07-29 | Date Exagen Inc. filed its Form 10-Q, reporting shares outstanding. |
| 2025-08-13 | Date the Schedule 13G Amendment No. 3 was signed by Laurence W. Lytton. |
Keywords
Exagen Inc., Beneficial Ownership, Schedule 13G, SEC Filing, Investor Disclosure, Common Stock, EXGN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.